Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials
出版年份 2021 全文链接
标题
Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials
作者
关键词
-
出版物
BMJ-British Medical Journal
Volume -, Issue -, Pages m4573
出版商
BMJ
发表日期
2021-01-13
DOI
10.1136/bmj.m4573
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Sodium‐Glucose Cotransporter 2 Inhibition for the Prevention of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta‐Analysis
- (2020) Clare Arnott et al. Journal of the American Heart Association
- Dapagliflozin Versus Placebo on Left Ventricular Remodeling in Patients With Diabetes and Heart Failure: The REFORM Trial
- (2020) Jagdeep S.S. Singh et al. DIABETES CARE
- Effects of Glucagon‐Like Peptide‐1 Receptor Agonists, Sodium‐Glucose Cotransporter‐2 Inhibitors, and Their Combination on Endothelial Glycocalyx, Arterial Function, and Myocardial Work Index in Patients With Type 2 Diabetes Mellitus After 12‐Month Treatment
- (2020) Ignatios Ikonomidis et al. Journal of the American Heart Association
- Effects of canagliflozin in patients with type 2 diabetes and chronic heart failure: a randomized trial (CANDLE)
- (2020) Atsushi Tanaka et al. ESC Heart Failure
- 36-OR: Comparative Effectiveness of SGLT2 Inhibitors vs. GLP-1 Agonists
- (2020) INSIYA POONAWALLA et al. DIABETES
- Cardiovascular efficacy and safety of sodium-glucose co-transporter-2 inhibitors and glucagon-like peptide-1 receptor agonists: a systematic review and network meta-analysis
- (2019) H. Hussein et al. DIABETIC MEDICINE
- Efficacy and Safety of Empagliflozin in Renal Transplant Recipients With Posttransplant Diabetes Mellitus
- (2019) Thea Anine Strøm Halden et al. DIABETES CARE
- Effects of Dapagliflozin vs. Vildagliptin on Cardiometabolic Parameters in Diabetic Patients with Coronary Artery Disease: A Randomised Study
- (2019) A. Phrommintikul et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Safety and Effectiveness of Bexagliflozin in Patients With Type 2 Diabetes Mellitus and Stage 3a/3b CKD
- (2019) Andrew S. Allegretti et al. AMERICAN JOURNAL OF KIDNEY DISEASES
- Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
- (2019) Vlado Perkovic et al. NEW ENGLAND JOURNAL OF MEDICINE
- Albuminuria-lowering effect of dapagliflozin alone and in combination with saxagliptin and effect of dapagliflozin and saxagliptin on glycaemic control in patients with type 2 diabetes and chronic kidney disease (DELIGHT): a randomised, double-blind, placebo-controlled trial
- (2019) Carol Pollock et al. Lancet Diabetes & Endocrinology
- Effect of Empagliflozin on Left Ventricular Mass in Patients with Type 2 Diabetes and Coronary Artery Disease: The EMPA-HEART CardioLink-6 Randomized Clinical Trial
- (2019) Subodh Verma et al. CIRCULATION
- Effect of Empagliflozin on Endothelial Function in Patients With Type 2 Diabetes and Cardiovascular Disease: Results from the Multicenter, Randomized, Placebo-Controlled, Double-Blind EMBLEM Trial
- (2019) Atsushi Tanaka et al. DIABETES CARE
- 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD
- (2019) Francesco Cosentino et al. EUROPEAN HEART JOURNAL
- Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes
- (2019) Julio Rosenstock et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
- (2019) John J.V. McMurray et al. NEW ENGLAND JOURNAL OF MEDICINE
- SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis
- (2019) Brendon L Neuen et al. Lancet Diabetes & Endocrinology
- Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial
- (2019) Hiddo J L Heerspink et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- Effect of Sitagliptin on Coronary Flow Reserve Assessed by Magnetic Resonance Imaging in Type 2 Diabetic Patients With Coronary Artery Disease
- (2018) Keishi Moriwaki et al. CIRCULATION JOURNAL
- Renoprotective effects of canagliflozin, a sodium glucose cotransporter 2 inhibitor, in type 2 diabetes patients with chronic kidney disease: A randomized open-label prospective trial
- (2018) Hiroyuki Takashima et al. Diabetes & Vascular Disease Research
- Efficacy and safety of dapagliflozin in patients with type 2 diabetes and moderate renal impairment (chronic kidney disease stage 3A): The DERIVE Study
- (2018) Paola Fioretto et al. DIABETES OBESITY & METABOLISM
- Effect of pioglitazone on cardiometabolic profiles and safety in patients with type 2 diabetes undergoing percutaneous coronary artery intervention: a prospective, multicenter, randomized trial
- (2018) Atsushi Tanaka et al. HEART AND VESSELS
- Association Between Use of Sodium-Glucose Cotransporter 2 Inhibitors, Glucagon-like Peptide 1 Agonists, and Dipeptidyl Peptidase 4 Inhibitors With All-Cause Mortality in Patients With Type 2 Diabetes
- (2018) Sean L. Zheng et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Advances in the GRADE approach to rate the certainty in estimates from a network meta-analysis
- (2018) Romina Brignardello-Petersen et al. JOURNAL OF CLINICAL EPIDEMIOLOGY
- Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial
- (2018) Katherine R Tuttle et al. Lancet Diabetes & Endocrinology
- Effects of Vildagliptin on Ventricular Function in Patients With Type 2 Diabetes Mellitus and Heart Failure
- (2018) John J.V. McMurray et al. JACC-Heart Failure
- Liraglutide relieves cardiac dilated function than DPP-4 inhibitors
- (2018) Takeyuki Hiramatsu et al. EUROPEAN JOURNAL OF CLINICAL INVESTIGATION
- 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2019
- (2018) DIABETES CARE
- Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk
- (2018) Julio Rosenstock et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial
- (2018) Adrian F Hernandez et al. LANCET
- Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
- (2018) Stephen D. Wiviott et al. NEW ENGLAND JOURNAL OF MEDICINE
- A randomised, double-blind, trial of the safety and efficacy of omarigliptin (a once-weekly DPP-4 inhibitor) in subjects with type 2 diabetes and renal impairment
- (2017) Antonio Chacra et al. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
- Effect of sitagliptin on plaque changes in coronary artery following acute coronary syndrome in diabetic patients: The ESPECIAL-ACS study
- (2017) Shoichi Kuramitsu et al. Journal of Cardiology
- The GRADE Working Group clarifies the construct of certainty of evidence
- (2017) Monica Hultcrantz et al. JOURNAL OF CLINICAL EPIDEMIOLOGY
- Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
- (2017) Bruce Neal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Population-based incidence of diabetic ketoacidosis in type 2 diabetes: medical claims data analysis in Japan
- (2017) Masato Takeuchi et al. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY
- Development and validation of Risk Equations for Complications Of type 2 Diabetes (RECODe) using individual participant data from randomised trials
- (2017) Sanjay Basu et al. Lancet Diabetes & Endocrinology
- Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis
- (2017) Kåre I Birkeland et al. Lancet Diabetes & Endocrinology
- Ertugliflozin in Patients with Stage 3 Chronic Kidney Disease and Type 2 Diabetes Mellitus: The VERTIS RENAL Randomized Study
- (2017) George Grunberger et al. Diabetes Therapy
- Ertugliflozin in Patients with Stage 3 Chronic Kidney Disease and Type 2 Diabetes Mellitus: The VERTIS RENAL Randomized Study
- (2017) George Grunberger et al. Diabetes Therapy
- POSITIVE EFFECT OF THE PPAR-GAMMA AGONIST ROSIGLITAZONE ON HEMODYNAMIC RESPONSE TO EXERCISE IN TYPE 2 DIABETIC MEN AFTER CORONARY ARTERY BYPASS GRAFT SURGERY: A 1-YR RANDOMIZED STUDY
- (2016) A. Laberge et al. CANADIAN JOURNAL OF CARDIOLOGY
- Efficacy and safety of saxagliptin, a dipeptidyl peptidase-4 inhibitor, in hemodialysis patients with diabetic nephropathy: A randomized open-label prospective trial
- (2016) Masanori Abe et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Comparison of Clinical Outcomes and Adverse Events Associated With Glucose-Lowering Drugs in Patients With Type 2 Diabetes
- (2016) Suetonia C. Palmer et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- Introduction toBMJRapid Recommendations
- (2016) Reed A Siemieniuk et al. BMJ-British Medical Journal
- Introduction toBMJRapid Recommendations
- (2016) Reed A Siemieniuk et al. BMJ-British Medical Journal
- Comparison of effects of sitagliptin and voglibose on left ventricular diastolic dysfunction in patients with type 2 diabetes: results of the 3D trial
- (2015) Hiroki Oe et al. Cardiovascular Diabetology
- Pioglitazone Increases Circulating MicroRNA-24 With Decrease in Coronary Neointimal Hyperplasia in Type 2 Diabetic Patients – Optical Coherence Tomography Analysis –
- (2015) Soon Jun Hong et al. CIRCULATION JOURNAL
- Efficacy and Safety of Liraglutide Versus Placebo as Add-on to Glucose-Lowering Therapy in Patients With Type 2 Diabetes and Moderate Renal Impairment (LIRA-RENAL): A Randomized Clinical Trial
- (2015) Melanie J. Davies et al. DIABETES CARE
- Dapagliflozin’s Effects on Glycemia and Cardiovascular Risk Factors in High-Risk Patients With Type 2 Diabetes: A 24-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With a 28-Week Extension
- (2015) William T. Cefalu et al. DIABETES CARE
- A randomized, double-blind, placebo-controlled study on long-term efficacy and safety of ipragliflozin treatment in patients with type 2 diabetes mellitus and renal impairment: results of the Long-Term ASP1941 Safety Evaluation in Patients with Type 2 Dia
- (2015) A. Kashiwagi et al. DIABETES OBESITY & METABOLISM
- Epley and Semont maneuvers for posterior canal benign paroxysmal positional vertigo: A network meta-analysis
- (2015) Yun Liu et al. LARYNGOSCOPE
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
- (2015) Bernard Zinman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
- (2015) Marc A. Pfeffer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Development and validation of risk prediction equations to estimate future risk of blindness and lower limb amputation in patients with diabetes: cohort study
- (2015) J. Hippisley-Cox et al. BMJ-British Medical Journal
- Development and validation of risk prediction equations to estimate future risk of blindness and lower limb amputation in patients with diabetes: cohort study
- (2015) J. Hippisley-Cox et al. BMJ-British Medical Journal
- Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease
- (2014) J.-F. Yale et al. DIABETES OBESITY & METABOLISM
- Beneficial Effects of Pioglitazone on Retardation of Persistent Atrial Fibrillation Progression in Diabetes Mellitus Patients
- (2014) Bing Liu et al. International Heart Journal
- Insulin glargine effectively achieves glycemic control and improves insulin resistance in patients with early type 2 diabetes that exhibit a high risk for cardiovascular disease
- (2014) JILING LI et al. Experimental and Therapeutic Medicine
- Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial
- (2014) Anthony H Barnett et al. Lancet Diabetes & Endocrinology
- Efficacy and Safety of Sitagliptin in Patients With Type 2 Diabetes and ESRD Receiving Dialysis: A 54-Week Randomized Trial
- (2013) Juan C. Arjona Ferreira et al. AMERICAN JOURNAL OF KIDNEY DISEASES
- Derivation and Validation of a Renal Risk Score for People With Type 2 Diabetes
- (2013) C. R. Elley et al. DIABETES CARE
- Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease
- (2013) J.-F. Yale et al. DIABETES OBESITY & METABOLISM
- Evaluation of inconsistency in networks of interventions
- (2013) A. A. Veroniki et al. INTERNATIONAL JOURNAL OF EPIDEMIOLOGY
- Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control
- (2013) Donald E. Kohan et al. KIDNEY INTERNATIONAL
- Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes
- (2013) William B. White et al. NEW ENGLAND JOURNAL OF MEDICINE
- Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus
- (2013) Benjamin M. Scirica et al. NEW ENGLAND JOURNAL OF MEDICINE
- Graphical Tools for Network Meta-Analysis in STATA
- (2013) Anna Chaimani et al. PLoS One
- Effects of Low Dose Pioglitazone on Restenosis and Coronary Atherosclerosis in Diabetic Patients Undergoing Drug Eluting Stent Implantation
- (2013) Hye Won Lee et al. YONSEI MEDICAL JOURNAL
- Early Improvement in Carotid Plaque Echogenicity by Acarbose in Patients With Acute Coronary Syndromes
- (2012) Mitsumasa Hirano et al. CIRCULATION JOURNAL
- Efficacy and Safety of Sitagliptin Versus Glipizide in Patients With Type 2 Diabetes and Moderate-to-Severe Chronic Renal Insufficiency
- (2012) J. C. Arjona Ferreira et al. DIABETES CARE
- Long-Term Efficacy and Safety of Linagliptin in Patients With Type 2 Diabetes and Severe Renal Impairment: A 1-year, randomized, double-blind, placebo-controlled study
- (2012) J. B. McGill et al. DIABETES CARE
- Effects of Metformin Versus Glipizide on Cardiovascular Outcomes in Patients With Type 2 Diabetes and Coronary Artery Disease
- (2012) J. Hong et al. DIABETES CARE
- Effect of Thiazolidinedione Treatment on Proteinuria and Renal Hemodynamic in Type 2 Diabetic Patients with Overt Nephropathy
- (2012) F. Pistrosch et al. HORMONE AND METABOLIC RESEARCH
- Incidence of genital infection among patients with type 2 diabetes in the UK General Practice Research Database
- (2012) Ishan Hirji et al. JOURNAL OF DIABETES AND ITS COMPLICATIONS
- Pioglitazone reduces urinary albumin excretion in renin−angiotensin system inhibitor-treated type 2 diabetic patients with hypertension and microalbuminuria: the APRIME study
- (2011) Akizuki Morikawa et al. Clinical and Experimental Nephrology
- Safety and efficacy of vildagliptin versus placebo in patients with type 2 diabetes and moderate or severe renal impairment: a prospective 24-week randomized placebo-controlled trial
- (2011) V. Lukashevich et al. DIABETES OBESITY & METABOLISM
- The dipeptidyl peptidase-4 (DPP-4) inhibitor vildagliptin improves glycemic control in type 2 diabetic patients undergoing hemodialysis
- (2011) Midori Ito et al. ENDOCRINE JOURNAL
- Long-term treatment with the dipeptidyl peptidase-4 inhibitor saxagliptin in patients with type 2 diabetes mellitus and renal impairment: a randomised controlled 52-week efficacy and safety study
- (2011) M. Nowicki et al. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
- Effect of Rosiglitazone on Progression of Coronary Atherosclerosis in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease
- (2010) Hertzel C. Gerstein et al. CIRCULATION
- The effects of rosiglitazone on atherosclerotic progression in patients with Type 2 diabetes at high cardiovascular risk
- (2010) M. S. Yee et al. DIABETIC MEDICINE
- Randomized comparison of the effects of rosiglitazone vs. placebo on peak integrated cardiovascular performance, cardiac structure, and function
- (2010) D. K. McGuire et al. EUROPEAN HEART JOURNAL
- Clinical effectiveness and safety evaluation of long-term pioglitazone treatment for erythropoietin responsiveness and insulin resistance in type 2 diabetic patients on hemodialysis
- (2010) Masanori Abe et al. EXPERT OPINION ON PHARMACOTHERAPY
- Checking consistency in mixed treatment comparison meta-analysis
- (2010) S. Dias et al. STATISTICS IN MEDICINE
- Predictive factors for in-stent late loss and coronary lesion progression in patients with type 2 diabetes mellitus randomized to rosiglitazone or placebo
- (2009) Aloke V. Finn et al. AMERICAN HEART JOURNAL
- Pioglitazone Reduces the Necrotic-Core Component in Coronary Plaque in Association With Enhanced Plasma Adiponectin in Patients With Type 2 Diabetes Mellitus
- (2009) Daisuke Ogasawara et al. CIRCULATION JOURNAL
- Long-term effects of pioglitazone in Japanese patients with type 2 diabetes without a recent history of macrovascular morbidity
- (2009) Kohei Kaku et al. CURRENT MEDICAL RESEARCH AND OPINION
- A Prospective, Multicenter, Randomized Trial to Assess Efficacy of Pioglitazone on In-Stent Neointimal Suppression in Type 2 Diabetes
- (2009) Tsutomu Takagi et al. JACC-Cardiovascular Interventions
- Rapid improvement of carotid plaque echogenicity within 1 month of pioglitazone treatment in patients with acute coronary syndrome
- (2008) Mitsumasa Hirano et al. ATHEROSCLEROSIS
- Comparison of Pioglitazone vs Glimepiride on Progression of Coronary Atherosclerosis in Patients With Type 2 Diabetes
- (2008) Steven E. Nissen et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Pioglitazone and Heart Failure: Results From a Controlled Study in Patients With Type 2 Diabetes Mellitus and Systolic Dysfunction
- (2008) Thomas D. Giles et al. JOURNAL OF CARDIAC FAILURE
- Incidence rates and treatment of neuropathic pain conditions in the general population☆
- (2008) Jeanne P. Dieleman et al. PAIN
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started